FutureTech II Acquisition Corp. enters amended merger with Longevity Biomedical; $100M enterprise value

FutureTech II Acquisition Corp.

Amended merger agreement filed Aug 6, 2025; combined company to list on Nasdaq as 'LBIO'.
Consideration: $100M less value of vested options converted, divided by $10 per share.
Merger contingent on Longevity acquisitions of Cerevast Medical and Aegeria Soft Tissue.
Closing expected Q4 2025; requires stockholder and regulatory approvals, fairness opinion.
Sponsor and Longevity stockholder support agreements remain in effect.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.